


CORRECTION

Correction: The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease

Mercè Borràs Sans, Miguel Pérez-Fontán, Montserrat Martínez-Alonso, Auxiliadora Bajo, Àngels Betriu, José M. Valdivielso, Elvira Fernández, on behalf of NEFRONA INVESTIGATORS

There are errors in the “Hemoglobin (mmol/L)” values in [Table 1](#), [Table 2](#) and [Table 3](#). Please see the corrected tables here.



 OPEN ACCESS

Citation: Borràs Sans M, Pérez-Fontán M, Martínez-Alonso M, Bajo A, Betriu À, Valdivielso JM, et al. (2018) Correction: The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease. PLoS ONE 13(6): e0200226. <https://doi.org/10.1371/journal.pone.0200226>

Published: June 28, 2018

Copyright: © 2018 Borràs Sans et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1. Main Baseline characteristics according to dialysis modality.

	PD ^a patients (n = 237)	HD ^b patients (n = 237)	p
Males (%)	137 (58)	146 (61.8)	0.45
Age (years)	52 [42;63]	55 [43;63]	0.11
Smoker (former/current) (%)	135 (57)	137 (58)	0.92
Diabetes (%)	43 (18.1)	43 (18.1)	1
Hypertension (%)	219 (92.4)	199 (84)	0.007
Dyslipidemia (%)	153 (64.6)	123 (47.7)	<0.001
Etiology of renal disease (%):			0.670
Diabetic nephropathy	25 (10.5)	27 (11.4)	
Vascular disease	23 (9.7)	29 (12.2)	
Others	189 (79.7)	181 (76.4)	
Dialysis time (months)	13.7 [6.2;28.9]	14.3 [6.4;28.6]	0.91
Body mass index (kg/m ²)	26.4 [23.3;29.2]	25.3 [23;28.6]	0.23
Systolic Blood Pressure (mmHg)	140 [129;159]	135 [120;151]	0.001
Diastolic Blood Pressure (mm Hg)	83 [77;94]	80 [70;88]	<0.001
Pulse Pressure (mmHg)	56 [45;69]	55 [46;63]	0.53
Serum glucose (mmol/L)	5.05 [2.96;6.10]	5.05 [4.56;6.10]	0.838
Urea (mmol/L)	21.5 [17.6;25.8]	20.8 [15.8;25]	0.07
Creatinine (μmol/L)	682.5 [519.8;884]	727.5 [574.6;884]	0.1
Total cholesterol (mmol/L)	4.58 [3.99;5.20]	3.91 [3.37;4.53]	<0.001
HDL-cholesterol (mmol/L)	1.22 [1.01;1.48]	1.09 [0.90;1.29]	<0.001
LDL-cholesterol (mmol/L)	2.66 [2.07;5.15]	2.07 [1.63;2.64]	<0.001
Triglycerides (mmol/L)	1.34 [1.07;1.87]	1.41 [1.03;1.92]	0.75
Serum uric acid (μmol/L)	345.1 [303.4;401.6]	362.9 [321.3;425.4]	0.006
hs C-Reactive Protein (nmol/L)	19 [8.95;49.9]	22.47 [10.09;58.66]	0.23
Albumin (mol/L)	0.59 [0.54;0.62]	0.59 [0.54;0.64]	0.025
Hemoglobin (mmol/L)	7.2 [7.01;8.01]	7.26 [6.70;7.76]	<0.001
Corrected calcium (mmol/L)	2.3 [2.20;2.42]	2.26 [2.16;2.36]	<0.001
Phosphate (mmol/L)	1.6 [1.35;1.84]	1.54 [1.25;1.79]	0.035
iPTH (pmol/L)	22.7 [14.9;35.4]	25.7 [14.3;36.4]	0.23
25-hydroxy-vitamin D (nmol/L)	28.9 [20.9;41.2]	37.4 [26.4;48.7]	<0.001
1-25-hydroxy-vitamin D (pmol/L)	13.6 [9.72;19.9]	13.8 [9.31;22.3]	0.54
Treatments			
Antihypertensive (%):	214 (90.3)	159 (67.1)	<0.001
ACEI ^c (%)	66 (27.8)	41 (17.3)	0.008
ARBs ^d (%)	111 (46.8)	54 (22.8)	<0.001
Diuretics (%)	128 (54)	45 (19)	<0.001
Statins (%)	137 (57.8)	110 (46.4)	0.017
Phosphate binders (%):	198 (83.5)	189 (79.7)	0.343
Binders without Ca ^e (%)	126 (53.2)	138(58.2)	0.309
Binders with Ca ^e (%)	42 (47.2)	40 (47.1)	1
Ca ^e intake (binders) (gr/day)	1.5 [1;2]	1.65 [1;3]	0.027
Calcitriol/Paricalcitol (%)	97 (40.9)	122 (51.5)	0.027
Calcifedol (%)			
Cholecalciferol (%)	27 (11.4)	8 (3.38)	0.002
Cinacalcet (%)	11(4.64)	8 (3.38)	0.640
Antiplatelet drugs (%):	27 (24.1)	68 (28.7)	0.297

(Continued)

Table 1. (Continued)

	PD ^a patients (n = 237)	HD ^b patients (n = 237)	p
ESA ^f (%)	181 (76.4)	198 (83.5)	0.066
Renal transplantation centre (%)	88 (37.1)	62 (26.2)	0.014
Plaque presence (%)	123 (51.9)	143 (60.3)	0.08
Number of territories with plaque	2 [1.0;3.0]	2 [1.0;3.0]	0.285
cIMT ^g (mm)	0.65 [0.56;0.79]	0.70 [0.6;0.84]	0.009
Ankle-Brachial index (%)			
ABI < 0.9	37 (15.7)	23 (9.91)	0.08
ABI >0.9-<1.4	175 (74.5)	144 (62.1)	0.005
ABI > 1.4	23 (9.79)	65 (28)	<0.001

Data are presented as median [interquartile range], mean (standard deviation) or n(%).

^a Peritoneal dialysis

^b Hemodialysis

^c Angiotensin converting enzyme inhibitors

^d Angiotensin II receptor blockers

^e Calcium

^f Erythropoiesis stimulating agents

^g Common carotid artery intima media thickness

<https://doi.org/10.1371/journal.pone.0200226.t001>

Table 2. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.

	PD ^a patients (n = 82)	HD ^b patients (n = 85)	p
Males (%)	47 (57.3)	48 (52.2)	0.6
Age (years)	53 [42.5;63]	55 [44.8;64]	0.39
Smoker (former/current) (%)	49 (59.8)	48 (52.2)	0.9
Diabetes (%)	14 (17.1)	14 (15.2)	0.9
Hypertension (%)	75 (91.5)	79 (86)	0.359
Dyslipidemia (%)	58 (70.7)	55 (59.8)	0.176
Etiology of renal disease (%):			0.670
Diabetic nephropathy	7 (8.54)	8 (8.7)	
Vascular disease	8 (9.76)	13 (14.1)	
Others	67 (81.7)	71 (77.2)	
Dialysis time (months)	10.5 [4.46;19.2]	11.5 [5.82;25.8]	0.131
Body mass index (kg/m ²)	26.4 [23.3;28.4]	26.1 [23;4.32.2]	0.446
Systolic Blood Pressure (mmHg)	145 (24.4)	138 (21.8)	0.03
Diastolic Blood Pressure (mm Hg)	87.5 (12.2)	78.8 (13.3)	<0.001
Pulse Pressure (mmHg)	56 [44;69]	56.5 [47;70.2]	0.579
Serum glucose (mmol/L)	5.16 [4.72;5.61]	5.23 [4.55;6.05]	0.931
Urea (mmol/L)	22.11 (6.76)	20.31 (6.13)	0.053
Creatinine (μmol/L)	596.7 [468.5;792.1]	676.3 [583.4;837.2]	0.815
Total cholesterol (mmol/L)	4.75 [4.2;5.43]	3.9 [3.2;4.45]	0.258
HDL-cholesterol (mmol/L)	1.21 [1;1.52]	1.1 [0.88;1.21]	0.005
LDL-cholesterol (mmol/L)	3.46 [2.28;3.05]	3.36 [2.56;4.4]	<0.001

(Continued)

Table 2. (Continued)

	PD ^a patients (n = 82)	HD ^b patients (n = 85)	p
Triglycerides (mmol/L)	1.53 [1.09;2.02]	1.48 [1.13;1.94]	0.940
Serum uric acid (μmol/L)	350.4 (72.6)	369.4 (70.78)	0.093
hs C-Reactive Protein (nmol/L)	26.28 [10;61.24]	24 [10.47;62.48]	0.815
Albumin (mol/L)	0.59 [0.53;0.62]	0.59 [0.54;0.64]	0.471
Hemoglobin (mmol/L)	7.24 (0.80)	6.82 (0.84)	0.002
Corrected calcium (mmol/L)	2.32 [2.22;2.4]	2.25 [2.16;2.32]	0.031
Phosphate (mmol/L)	1.52[1.32;1.81]	1.55 [1.29;1.81]	0.965
iPTH (pmol/L)	21.1 [15.48;34.25]	26.51 [16.2;41]	0.182
25-hydroxy-vitamin D (nmol/L)	30.5 [21.75;43.75]	35.5 [27;48]	0.014
1-25-hydroxy-vitamin D (pmol/L)	15.45 [10.3;22.7]	14.4 [10.15;25.75]	0.862
Treatments			
Antihypertensive (%):	72 (87.8)	60 (65.2)	0.001
ACEI ^c (%)	20 (24.4)	15 (16.3)	0.255
ARBs ^d (%)	37 (45.1)	25 (27.2)	0.021
Diuretics (%)	27 (32.6)	28 (32.9)	0.837
Statins (%)	48 (58.3)	50 (54.3)	0.687
Phosphate binders (%):	66 (80.5)	68 (73.9)	0.396
Binders without Ca ^e (%)	38 (46.3)	48(52.2)	0.538
Binders with Ca ^e (%)	42 (47.2)	40 (47.1)	1
Ca ^e intake (binders) (gr/day)	1 [1;1.5]	1.5 [1;2.5]	0.03
Calcitriol/Paricalcitol (%)	34 (41.5)	44 (47.8)	0.490
Calcifedol (%)	8 (9.76)	5 (5.43)	0.428
Cholecalciferol (%)	2 (2.44)	4 (4.35)	0.685
Cinacalcet (%)	18 (22)	24 (26.1)	0.646
Antiplatelet drugs (%):	22 (26.8)	27 (29.3)	0.842
ESA ^f (%)	62 (75.6)	77 (83.7)	0.255
Renal transplantation centre (%)	27 (32.9)	20 (21.7)	0.137
Plaque presence (%)	44 (53.7)	53 (57.6)	0.711
Number of territories with plaque	2 [1.0;2.0]	2 [1.0;3.0]	0.149
cIMT ^g (mm)	0.65 [0.57;0.75]	0.72 [0.62;0.86]	0.005
Ankle-Brachial index (%)			<0.001
ABI <0.9	10 (12.2)	7 (7.78)	
ABI >0.9-<1.4	66 (80.5)	55 (61.1)	
ABI > 1.4	6 (7.32)	21 (31.1)	

Data are presented as median [interquartile range], mean (standard deviation) or n (%).

^a Peritoneal dialysis

^b Hemodialysis

^c Angiotensin converting enzyme inhibitors

^d Angiotensin II receptor blockers

^e Calcium

^f Erythropoiesis stimulating agents

^g Common carotid artery intima media thickness

<https://doi.org/10.1371/journal.pone.0200226.t002>

Table 3. Main Baseline characteristics of patients with 2-years follow-up according to dialysis modality.

	AVD ^a progression (n = 89)	Non AVD progression (n = 85)	p
Males (%)	50 (56.2)	45 (52.9)	0.78
Age (years)	57 [48;65]	50 [39;62]	0.004
Smoker (former/current) (%)	53 (59.6)	44 (51.8)	0.38
Diabetes (%)	20 (22.5)	8 (9.41)	0.033
Hypertension (%)	79 (88.8)	75 (88.2)	1
Dyslipidemia (%)	59 (66.3)	54 (63.5)	0.824
Etiology of renal disease (%):			0.165
Diabetic nephropathy	25 (10.5)	27 (11.4)	
Vascular disease	23 (9.7)	29 (12.2)	
Others	69 (77.5)	69 (81.2)	
Dialysis time (months)	10.2 [4.4;23.2]	11.8 [6.47;22.5]	0.27
Body mass index (kg/m ²)	27 [23.6;30.7]	26.1 [23.1;28.8]	0.156
Systolic Blood Pressure (mmHg)	142 (24.3)	141 (24.3)	0.735
Diastolic Blood Pressure (mm Hg)	82 (13.5)	83.9 (13.5)	0.343
Pulse Pressure (mmHg)	60 [44;74]	56 [45;66]	0.326
Serum glucose (mmol/L)	5.18 [4.54;6.10]	5.05 [4.49;5.66]	0.157
Urea (mmol/L)	18.3 (5.25)	18.3 (5.21)	0.984
Creatinine (μmol/L)	610 [486.2;797.4]	662.1 [557.8;839.8]	0.089
Total cholesterol (mmol/L)	4.14 [3.63;4.89]	4.45 [3.57;5.33]	0.258
HDL-cholesterol (mmol/L)	1.10 [0.93;1.39]	1.16 [0.96;1.37]	0.561
LDL-cholesterol (mmol/L)	2.30 [1.85;2.82]	2.61 [1.81;2.98]	0.264
Triglycerides (mmol/L)	1.51 [1.11;2.10]	1.38 [1.07;1.92]	0.528
Serum uric acid (μmol/L)	370.5 (72.6)	350.4 (70.8)	0.084
hs C-Reactive Protein (nmol/L)	37.7 [13.8;65.9]	18.5 [8.4;54.2]	0.04
Albumin (mol/L)	0.59 [0.0.53;0.63]	0.59 [0.54;0.62]	0.613
Hemoglobin (mmol/L)	7 (0.95)	7 (0.80)	0.962
Corrected calcium (mmol/L)	2.31 [2.19;2.4]	2.26 [2.12;2.37]	0.419
Phosphate (mmol/L)	1.52 [1.26;1.81]	1.55 [1.36;1.84]	0.292
iPTH (pmol/L)	24.7 [15.9;38.1]	23.3 [15.27;36.7]	0.586
25-hydroxy-vitamin D (nmol/L)	30.9 [22.8;42.9]	36.4 [26.7;48.7]	0.043
1-25-hydroxy-vitamin D (pmol/L)	14.9 [10.0;24.5]	13.6 [9.7;22.3]	0.602
Treatments			
Antihypertensive (%):	68 (76.4)	64 (75.3)	1
ACEI ^b (%)	18 (20.2)	17 (20)	1
ARBs ^c (%)	29 (32.6)	33 (38.8)	0.483
Diuretics (%)	27 (32.6)	28 (32.9)	0.837
Statins (%)	51 (57.3)	47 (55.3)	0.9
Phosphate binders (%):	68 (76.4)	66 (77.6)	0.98
Binders without Ca ^d (%)	39 (43.8)	47 (55.3)	0.173
Binders with Ca ^d (%)	42 (47.2)	40 (47.1)	1
Ca ^d intake (binders) (gr/day)	1 [1;1.5]	1.5 [1;2.5]	
Calcitriol/Paricalcitol (%)	45 (50.6)	33 (38.8)	0.16
Calcifedol (%)	9 (10.1)	4 (4.71)	0.286
Cholecalciferol (%)	3 (3.37)	3 (3.53)	1
Cinacalcet (%)	19 (21.3)	23 (27.1)	0.482
Antiplatelet drugs (%):	27 (30.3)	22 (25.9)	0.628

(Continued)

Table 3. (Continued)

	AVD ^a progression (n = 89)	Non AVD progression (n = 85)	p
ESA ^c (%)	66 (74.2)	73 (85.9)	0.082
Renal transplantation centre (%)	22 (24.7)	25 (29.4)	0.599
Plaque at baseline (%)	64 (71.9)	33 (33.8)	<0.001
Number of territories with plaque	2 [1.0;3.0]	2 [1.0;3.0]	0.398
cIMT ^f (mm)	0.73 [0.65;0.89]	0.64 [0.56;0.74]	<0.001
Ankle-Brachial index (%)			
ABI <0.9	11 (12.5)	6 (7.14)	0.357
ABI >0.9-<1.4	57 (64.8)	64 (76.2)	0.141
ABI > 1.4	20 (22.7)	14 (16.7)	0.420
Dialysis modality:			0.437
Hemodialysis	44 (49.4)	48 (56.5)	
Peritoneal dialysis	45 (50.6)	37 (43.5)	

Data are presented as median [interquartile range], mean (standard deviation) or n (%).

^a Atheromatous vascular disease

^b Angiotensin converting enzyme inhibitors

^c Angiotensin II receptor blockers

^d Calcium

^e Erythropoiesis stimulating agents

^f Common carotid artery intima media thickness

<https://doi.org/10.1371/journal.pone.0200226.t003>

Reference

1. Borràs Sans M, Pérez-Fontán M, Martínez-Alonso M, Bajo A, Betriu À, Valdivielso JM, et al. (2017) The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease. PLoS ONE 12(11): e0186921. <https://doi.org/10.1371/journal.pone.0186921> PMID: 29095847